title: Few positives for triple-negative breast cancer.
authors: Karyn
authors: K
authors: Hede
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000378:metabolism*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism*; D002166:Camptothecin / Q000031:analogs & derivatives / Q000627:therapeutic use; D002626:Chemistry, Pharmaceutical; D018572:Disease-Free Survival; D034261:Epothilones / Q000627:therapeutic use; D005260:Female; D019398:Genes, BRCA1; D006801:Humans; D000077146:Irinotecan; D010298:Parity; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism; D011960:Receptors, Estrogen / Q000378:metabolism; D011980:Receptors, Progesterone / Q000378:metabolism; D012307:Risk Factors; D016896:Treatment Outcome; D050257:Tubulin Modulators / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D014408:Biomarkers, Tumor; D002166:Camptothecin; D034261:Epothilones; D000077146:Irinotecan; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D050257:Tubulin Modulators; C090712:iniparib; C430592:ixabepilone